Asymmetry in Therapeutics

A pre-revenue therapeutics name is not a stock so much as a portfolio of call options on biology. Its value is a risk-adjusted NPV, where each future cash flow is scaled by the probability of technical success at its development stage.

The power of rNPV is that it decouples technical risk, which is binary and resolved at a specific catalyst, from financial risk, which is continuous over time. The most common and most expensive error in the sector is to conflate the two, and that conflation is precisely what creates the dislocation.

Owned correctly, these assets are long convexity. There is a floor, whether cash, NAV, platform or out-licence value, and an uncapped ceiling in approval and label expansion. Limited downside, non-linear upside.

Management holds real options at every node: continue, delay, abandon, out-licence, or expand into a new indication. Markets systematically misprice volatility and time value on convex, binary assets, and they do it most under narrative and anchoring bias, extrapolating the last data point as though it were the last word.

Unmet need is necessary but not sufficient. The trade lives at the intersection of high unmet need and a wide value dislocation, the 2x2 corner where a genuine option trades below its intrinsic value.

Our variant perception is mechanistic, not sentiment-driven: does the biology make causal sense, is the catalyst path mispriced, and is enterprise value sitting below a defensible rNPV floor? Convexity only rewards those who survive to the catalyst, so we underwrite cash runway and safety risk first, before any conviction in the upside.